A Model of Placebo Response in Antidepressant Clinical Trials
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Placebo response in clinical trials of antidepressant medications is substantial and has been increasing. High placebo response rates hamper efforts to detect signals of efficacy for new antidepressant medications, contributing to trial failures and delaying the delivery of new treatments to market. Media reports seize upon increasing placebo response and modest advantages for active drugs as reasons to question the value of antidepressant medication, which may further stigmatize treatments for depression and dissuade patients from accessing mental health care. Conversely, enhancing the factors responsible for placebo response may represent a strategy for improving available treatments for major depressive disorder. A conceptual framework describing the causes of placebo response is needed in order to develop strategies for minimizing placebo response in clinical trials, maximizing placebo response in clinical practice, and talking with depressed patients about the risks and benefits of antidepressant medications. In this review, the authors examine contributors to placebo response in antidepressant clinical trials and propose an explanatory model. Research aimed at reducing placebo response should focus on limiting patient expectancy and the intensity of therapeutic contact in antidepressant clinical trials, while the optimal strategy in clinical practice may be to combine active medication with a presentation and level of therapeutic contact designed to enhance treatment response.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are several potential explanations, as many factors have been associated with higher placebo response rates, such as randomisation ratio and the expectation of receiving an active treatment, the therapeutic setting, or the frequency of study visits.24”
In the citing paper
“Late-life depression (LLD) is a common and debilitating condition, with less frequent remission and more frequent recurrence following first-line antidepressant treatment compared to depression experienced earlier in life1–7.”
From Psychobiological factors of resilience and depression in late life (2019) · cites this paper as [5]
In the citing paper
“Whilst previous meta-analyses have demonstrated that control group responses (CGRs) can negatively influence antidepressant efficacy”
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Measurement and Control of Response Bias
Paulhus, D. L. (1991) · Measures of Personality and Social Psychological Attitudes · doi:10.1016/b978-0-12-590241-0.50006-x · Cited by 3,598
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Regression to the mean: what it is and how to deal with it
Barnett, A. G. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh299 · Cited by 1,988 · cited 1×
“One source of apparent symptom change in antidepressant trials is regression to the mean, which is a statistical phenomenon occurring when repeated measurements associated with random error are made on the same subject over time (32).”
BackgroundPlacebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“In antidepressant trials for adults, placebo response averages 31% compared to a mean medication response of 50%, and it has risen at a rate of 7% per decade over the past 30 years (1).”
BackgroundThe Functional Neuroanatomy of the Placebo Effect
Mayberg, H. S., Silva, J. A., Brannan, S. K., Tekell, J. L., Mahurin, R. K., McGinnis, S., & Jerabek, P. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.728 · Cited by 720
The Placebo Effect: Dissolving the Expectancy Versus Conditioning Debate.
Stewart-Williams, S., & Podd, J. (2004) · Psychological Bulletin · doi:10.1037/0033-2909.130.2.324 · Cited by 664
Lespérance, F., Frasure-Smith, N., Koszycki, D., Laliberté, M.-A., van Zyl, L. T., Baker, B., Swenson, J. R., Ghatavi, K., Abramson, B. L., Dorian, P., et al. (2007) · JAMA · doi:10.1001/jama.297.4.367 · Cited by 658
Newcome, F. (1968) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.31.4.409-c · Cited by 629
Research works printed but not linked: 8
- Hooper M, Amsterdam JD: Do clinical trials reflect drug potential? A review of FDA evaluation of new antidepressants, in 39th Annual Meeting Abstracts of Poster Presentations, New Clinical Drug Evaluation Unit Program, 1999
- World Health Organization, 2004, The World Health Report 2004: Changing History, Annex Table 3: Burden of Disease in DALYs by Cause, Sex, and Mortality Stratum in WHO Regions, Estimates for 2002
- Bass MJ, 1986, J Fam Pract, 23, 43
- Stettin GD, 2006, Am J Manag Care, 12, 453
- 10.1037/0022-006X.60.5.664 · DOI · Paper page
- 10.1001/jama.1984.03350060032024 · DOI · Paper page
- Liberman RP, 1967, Neuropsychopharmacology, 5, 557
- Doongaji DR, 1978, J Postgrad Med, 24, 147
Cited by
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418
“There is a well-known and substantial placebo response in antidepressant clinical trials due in large part to patient expectations and the intensity of therapeutic contacts (Rutherford and Roose, 2013; Leuchter et al., 2014).”
BackgroundCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · Focus · doi:10.1176/appi.focus.16407 · Cited by 328
Motter, J. N., Pimontel, M. A., Rindskopf, D., Devanand, D. P., Doraiswamy, P. M., & Sneed, J. R. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.09.022 · Cited by 303
Blinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Aday, J. S., Heifets, B. D., Pratscher, S. D., Bradley, E., Rosen, R., & Woolley, J. D. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06123-7 · Cited by 237
Psychobiological factors of resilience and depression in late life
Laird, K. T., Krause, B., Funes, C., & Lavretsky, H. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0424-7 · Cited by 229
Furukawa, T. A., Cipriani, A., Atkinson, L. Z., Leucht, S., Ogawa, Y., Takeshima, N., Hayasaka, Y., Chaimani, A., & Salanti, G. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30307-8 · Cited by 219
Lavretsky, H., Reinlieb, M., St. Cyr, N., Siddarth, P., Ercoli, L. M., & Senturk, D. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14070889 · Cited by 184
Patient Expectancy as a Mediator of Placebo Effects in Antidepressant Clinical Trials
Rutherford, B. R., Wall, M. M., Brown, P. J., Choo, T.-H., Wager, T. D., Peterson, B. S., Chung, S., Kirsch, I., & Roose, S. P. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16020225 · Cited by 183
“, one or more medications with no placebo group) (11).”
BackgroundSelf-citationRazza, L. B., Moffa, A. H., Moreno, M. L., Carvalho, A. F., Padberg, F., Fregni, F., & Brunoni, A. R. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.10.016 · Cited by 172
Tabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21080800 · Cited by 140
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Pimontel, M. A., Rindskopf, D., Rutherford, B. R., Brown, P. J., Roose, S. P., & Sneed, J. R. (2016) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.05.010 · Cited by 110
Self-citationRational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Masi, A., Lampit, A., Glozier, N., Hickie, I. B., & Guastella, A. J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.143 · Cited by 78
Faria, V., Gingnell, M., Hoppe, J. M., Hjorth, O., Alaie, I., Frick, A., Hultberg, S., Wahlstedt, K., Engman, J., Månsson, K. N. T., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.09.031 · Cited by 70
Basavaraju, R., Ithal, D., Thanki, M. V., Ramalingaiah, A. H., Thirthalli, J., Reddy, R. P., Brady, R. O., Halko, M. A., Bolo, N. R., Keshavan, M. S., et al. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.10.005 · Cited by 70
Krause, M., Gutsmiedl, K., Bighelli, I., Schneider-Thoma, J., Chaimani, A., & Leucht, S. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.07.130 · Cited by 65
Rief, W., Barsky, A. J., Bingel, U., Doering, B. K., Schwarting, R., Wöhr, M., & Schweiger, U. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.11.008 · Cited by 67
Stubbs, B., Vancampfort, D., Rosenbaum, S., Ward, P. B., Richards, J., Ussher, M., & Schuch, F. B. (2016) · Sports Medicine · doi:10.1007/s40279-015-0441-5 · Cited by 66
“There are concerns about increasing evidence of pronounced placebo responses in studies of antidepressant medication, making it more challenging for novel medications to demonstrate effectiveness [17, 18].”
BackgroundThe placebo-nocebo response: controversies and challenges from clinical and research perspective
Jakovljevic, M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.11.014 · Cited by 63
“…rate is associated with more study sites, poor rater blinding, multiple active treatment arms, lower probability of receiving inactive control, single baseline rating, briefer duration of symptoms in current episode, more study visits, optimistic/enthusiastic clinicians (Rutherford and Rose, 2012).”
BackgroundLavretsky, H., Laird, K. T., Krause-Sorio, B., Heimberg, B. F., Yeargin, J., Grzenda, A., Wu, P., Thana-Udom, K., Ercoli, L. M., & Siddarth, P. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.08.011 · Cited by 61
Zilcha-Mano, S., Keefe, J. R., Chui, H., Rubin, A., Barrett, M. S., & Barber, J. P. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10081 · Cited by 55
Kent, J. M., Daly, E., Kezic, I., Lane, R., Lim, P., De Smedt, H., De Boer, P., Van Nueten, L., Drevets, W. C., & Ceusters, M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.01.009 · Cited by 53
Zilcha-Mano, S., Roose, S. P., Brown, P. J., & Rutherford, B. R. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00293 · Cited by 53
Self-citationMofsen, A. M., Rodebaugh, T. L., Nicol, G. E., Depp, C. A., Miller, J. P., & Lenze, E. J. (2019) · JMIR Mental Health · doi:10.2196/11845 · Cited by 51
Cuijpers, P., Karyotaki, E., Andersson, G., Li, J., Mergl, R., & Hegerl, U. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.06.005 · Cited by 44
“positive effects and hope in the psychological intervention in patients, therapists and researchers, and increases in frustration and despair (nocebo effects) [28] in the patients in the control condition, inflating the effect sizes of psychotherapy [26,59].”
BackgroundGommoll, C. P., Greenberg, W. M., & Chen, C. (2014) · Journal of Drug Assessment · doi:10.3109/21556660.2014.884505 · Cited by 43
Dichtel, L. E., Nyer, M., Dording, C., Fisher, L. B., Cusin, C., Shapero, B. G., Pedrelli, P., Kimball, A. S., Rao, E. M., Mischoulon, D., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12887 · Cited by 40
Umbricht, D., Niggli, M., Sanwald-Ducray, P., Deptula, D., Moore, R., Grünbauer, W., Boak, L., & Fontoura, P. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12470 · Cited by 39
Cheng, Q., Huang, J., Xu, L., Li, Y., Li, H., Shen, Y., Zheng, Q., & Li, L. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz062 · Cited by 38
Dold, M., Bartova, L., & Kasper, S. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa034 · Cited by 34
“…be considered that investigations focusing on the mechanisms of placebo response in clinical trials revealed an association between high likelihood for receiving active treatment and increased response, mainly due to enhanced hope induction (Rutherford and Roose, 2013; Kasper and Dold, 2015).”
BackgroundHas psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety
Rasmussen, K. G. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.01.002 · Cited by 32
The conundrum of depression clinical trials: one size does not fit all
Khan, A., Mar, K. F., & Brown, W. A. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000229 · Cited by 30
“Such expectancy has been shown to increase the magnitude of both placebo response and AD response (Papakostas and Fava, 2009; Sinyor et al., 2010; Rutherford and Roose, 2013; Berna et al., 2017).”
BackgroundOptimizing patient expectancy in the pharmacologic treatment of major depressive disorder
Zilcha-Mano, S., Brown, P. J., Roose, S. P., Cappetta, K., & Rutherford, B. R. (2019) · Psychological Medicine · doi:10.1017/s0033291718003343 · Cited by 29
“Introduction Non-pharmacological factors, rather than the effects of antidepressant medication, appear to be responsible for much of the change observed in patients receiving antidepressants for major depressive disorder (MDD) (Rutherford and Roose, 2013).”
BackgroundInfluentialSelf-citationResilience predicts remission in antidepressant treatment of geriatric depression
Laird, K. T., Lavretsky, H., St. Cyr, N., & Siddarth, P. (2018) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4953 · Cited by 23
(2014) · Europe PMC (PubMed Central) · Cited by 24
The antidepressant standoff: Why it continues and how to resolve it
Ormel, J., Spinhoven, P., de Vries, Y. A., Cramer, A. O. J., Siegle, G. J., Bockting, C. L. H., & Hollon, S. D. (2020) · Psychological Medicine · doi:10.1017/s0033291719003295 · Cited by 22
Neural mechanisms of expectancy-based placebo effects in antidepressant clinical trials
Zilcha-Mano, S., Wang, Z., Peterson, B. S., Wall, M. M., Chen, Y., Wager, T. D., Brown, P. J., Roose, S. P., & Rutherford, B. R. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.05.023 · Cited by 21
Self-citationEfficacy of antidepressants: bias in randomized clinical trials and related issues
Wang, S.-M., Han, C., Lee, S.-J., Jun, T.-Y., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1377070 · Cited by 20
Blinding and expectancy confounds in psychedelic randomised controlled trials
Muthukumaraswamy, S., Forsyth, A., & Lumley, T. (2021) · doi:10.31234/osf.io/q2hzm · Cited by 15
The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder
Castagna, P. J., Farahdel, E., Potenza, M. N., & Crowley, M. J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2199921 · Cited by 3
Metadata
- Authors
- Rutherford, B. R., & Roose, S. P.
- Affiliations
- New York State Psychiatric Institute (US)
- ORCID
- Rutherford, Bret R.
- Venue
- American Journal of Psychiatry
- Published
- 2013-07
- Volume
- 170
- Issue
- 7
- Pages
- 723-733
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- PMC
- PMC3628961
- OpenAlex
- W2147111327
- Cited by
- 268
- References
- 63
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 16 · 2023: 15 · 2022: 18 · 2021: 23 · 2020: 18 · 2019: 27 · 2018: 23 · 2017: 26 · 2016: 10 · 2015: 28 · 2014: 30 · 2013: 4
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (K23MH085236, T32MH015144)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- placebo response, antidepressants, major depressive disorder, clinical trial design, therapeutic contact, depression treatment, antidepressant efficacy
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Humans, Models, Psychological, Placebo Effect, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.